 IXICO offers significant upside now it has strengthened its balance sheet
13 Feb 2025 GMT, First published: 12:32 12 Feb 2025 GMT
IXICO PLC -
With a stronger balance sheet secured, Cavendish believes IXICO PLC (AIM:IXI, OTC:PHYOF) shares offer significant upside for investors.
The med-tech firm, which specialises in AI-driven imaging for neurological disorders, has repositioned itself for sustainable revenue growth following a challenging period.
Cavendish notes that October's £4 million investment round will support expansion into larger therapy areas and a return revenue growth and enable it to reach profitability.
IXICO is a leading player in neuroimaging for clinical trials, particularly in Huntington’s disease. It recently announced a key milestone in its work with the Huntington’s Disease Imaging Harmonisation consortium, successfully analysing over 6,000 MRI scans to refine biomarkers for disease staging.
These biomarkers could help improve patient selection and trial design, making IXICO an attractive partner for pharmaceutical firms conducting research in neurodegenerative diseases.
The company’s IXIQ.Ai platform, which leverages artificial intelligence to analyse brain imaging, has shown strong potential beyond Huntington’s disease.
Cavendish highlights that IXICO’s technology could be applied to Alzheimer’s and Parkinson’s disease, two areas with growing demand for precision medicine. Recent regulatory approvals for Alzheimer’s treatments have renewed industry interest, opening opportunities for IXICO to expand its services.
IXICO’s financial position has also improved. The company raised additional funds to support its technology development and strategic partnerships. Huntington’s disease accounts for over half of IXICO’s clinical trial order book, with multiple long-term contracts in place.
Cavendish sees this as a stable foundation for revenue growth while the company broadens its reach into other neurological conditions.
Despite a broader slowdown in clinical trial initiations, Cavendish expects IXICO to benefit as the market normalises. The company’s ability to offer advanced imaging biomarkers positions it well to secure contracts with major pharmaceutical firms.
Cavendish also points to IXICO’s established industry relationships and its participation in major consortia as key strengths.
Overall, Cavendish maintains a positive outlook on IXICO, citing its improved financial footing, strategic positioning in high-demand therapy areas, and the potential for long-term growth in the neuroimaging sector.
"With a stronger balance sheet secured, we believe IXICO shares offer significant upside for investors," investors were told. |
Hoping this could be an interesting recovery play for 25'...... |
It is not always the case with Paul Hill— here he is so far off-piste I worry he might break something. Ixico is not a dominant player in AD; that's their view, not mine. They have potential but will need to run through early-stage trials first. The industry is moving towards AD diagnosis without imaging, as blood based biomarker technology starts to replace the need for PET, MRI or other imaging modalities. This technology is now validated and is now starting to be rolled out, though it will take time, as everything in this space does, but it is the direction of travel.
As for the AD post-market surveillance oportunity, Eisai's subcutaneous leqembi formulation, which will be on the market in the next 18 months, has much lower levels of ARIA than the infused version. Initial results from Roche's trontinemab phase 1b/2a clinical trial showed a significant reduction in ARIA occurrence compared to both leqembi and kinsula. This will need to be confirmed in a much larger trial, but again, the trend is towards much fewer ARIA-related events as DMT landscape develops.. If the trontinemab safety data is confirmed and it proves effective, there would be a strong case for discontinuing the FDA post-market surveillance requirements in place for all amyloid-clearing monoclonal antibodies. |
Vox podcast video with Paul hill I could not buy any earlier |
What has sparked the flurry recently here...? |
Thursday's article on IXICO published by Vox markets - "The brains behind brain scans." |
Could recover very nicely here... |
On paper at least a very strange choice for the new CEO, hard to see how he is going to change things meaningfully in the near/medium term. That said he should be given time to prove himself. Now they can focus on the a Capital Raise which they are going to need. |
200k a year over 5 years is not going to fill the negative cash flow hole that they freely admit to. As you well know management will not let the cash balances go below a certain point. The old saying goes raise when you can, not when you have to. Any raise is going to hurt but they need to avoid a death rattle raise in which existing holders are completley crushed. |
mms ready to let go |
As of 29 February, Ixico said it maintained a robust balance sheet, with £2.8m in cash reserves with no outstanding debt. So plenty of cash. This is due a major bounce up |
lovely £1million pound contract win today |
(Sharecast News) - Precision analytics company Ixico announced a new contract valued at over £1m on Wednesday.
The AIM-traded firm said the contract, awarded by a top-five contract research organisation (CRO) on behalf of a new pharmaceutical client, would involve providing imaging biomarker services for a phase three clinical trial targeting a type of Parkinsonian disorder.
It said the trial was set to run for just under five years, further establishing Ixico's expertise and expanding its footprint in the neuroimaging and biomarker space.
"Following the new contract win announced on 23 May in Alzheimer's disease, we are delighted to be announcing the award of a contract from a new client to support the development of a promising treatment targeting a Parkinsonian disorder," said chief executive officer Giulio Cerroni.
"We are pleased that our expertise in providing imaging analysis and radiological reads across clinical trials for a broadening range of neurodegenerative disorders, is increasingly recognised across the drug development industry and continues to attract new sponsors seeking these expert services." |
BUYING PRESSURE BUILDING UP SHOULD BREAKOUT THGIS AFTERNOON |
It is going to need a lot more than GBP 1 million over 5 years to avoid a CR. According to their last IMC presentation they are @GBP 1.8 million per year of revenue short of cash flow breakeven. |
7.50 paid and mms ready and primed to tick up |
in the TOP 10 GAINER ON THE LEADERBOARD NOW ....MOVING UP SWIFTLY |
market makers ticking up |
up 12 percent |
Great to see contract news like this, not only for the bottom line but also credibility..... |
RNS OUT -£1M Contract win .....could see 10.00+ today |
up 10 percent |
Have you finished pumping & dumping KPRZ, Cityspiv2874? 😂😂 |
reversal bounce breakout coming |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
